[Featured Stock] SMAC Rises on Announcement of KCDC Antibody Treatment Results Expected
[Asia Economy Reporter Minwoo Lee] Esmac's stock price is on the rise. This appears to be due to the spotlight on its subsidiary DynoNA developing antibody treatment-related technology, following the government's announcement of upcoming results on 'antibody treatment' for COVID-19.
As of 10:25 AM on the 13th, Esmac is trading at 1,645 KRW, up 11.15% from the previous day. This is likely because the Korea Disease Control and Prevention Agency (KDCA) announced it would reveal progress in antibody treatment methods after achieving results in plasma therapy, which involves transfusing blood from recovered COVID-19 patients to severe cases.
On the 11th, Kwon Jun-wook, head of the Central Disease Control Headquarters at KDCA, stated at a regular briefing, "We expect to soon disclose advanced progress centered on leading companies currently researching antibody treatment." While plasma therapy transfuses blood containing virus antibodies from recovered patients to others, antibody treatment directly produces antibodies that specifically respond to COVID-19.
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- "If Both Spouses Work There, How Much Would They Make?" "They Earn More Than Me, and I'm a Doctor"... Envy Erupts Over Samsung Electronics' Bonus
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Esmac's subsidiary DynoNA is reported to have completed a technical review aimed at discovering neutralizing antibodies against the COVID-19 virus from the blood of recovered patients.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
